Burnouf Thierry, Goubran Hadi Alphonse, Radosevich Miryana, Sayed Makram A, Gorgy George, El-Ekiaby Magdy
Human Plasma Product Services, Lille, France.
Transfusion. 2006 Dec;46(12):2100-8. doi: 10.1111/j.1537-2995.2006.01035.x.
Solvent/detergent (S/D) inactivates enveloped viruses in plasma. The current technology requires a plasma fractionation facility and is applied to large plasma pools, which increases the cost and risks of exposure to S/D-resistant pathogens and lowers the content of protein S and alpha2-antiplasmin. Two S/D treatment procedures for single donations or minipools of plasma have been developed with a single-use bag system.
Frozen plasma samples were thawed and treated in disposable bags with either 2 percent tri(n-butyl)phosphate (TnBP) at 37 degrees C or 1 percent TnBP and 1 percent Triton X-45 at 31 degrees C for 4 hours. Plasma samples were extracted three times with 7.5 percent sterile castor oil to remove TnBP and Triton X-45. The TnBP-treated plasma samples were further subjected to a clarifying centrifugation (3800 x g, 30 min). Final plasma samples were dispensed into individual bags and frozen at -30 degrees C. Plasma quality was assessed at each step of the procedures.
Both processes yielded greater than 90 percent mean recovery of coagulation factors (clottable fibrinogen, von Willebrand factor, and factors VIII, V, VII, IX, X, and XI), anticoagulants (protein C, protein S), protease inhibitors (antithrombin, alpha2-antiplasmin), total protein, albumin, and immunoglobulins. Global coagulation tests of the treated plasma samples were normal. Final TnBP and Triton X-45 content was less than 10 and 50 ppm, respectively.
S/D treatment of plasma can be performed in a closed-bag system under conditions that maintain plasma protein quality. The technology is simple, presents advantages over the industrial large-scale S/D plasma process, and could be performed in blood centers.
溶剂/去污剂(S/D)可使血浆中的包膜病毒失活。当前技术需要血浆分离设施,并应用于大量血浆池,这增加了接触耐S/D病原体的成本和风险,同时降低了蛋白S和α2-抗纤溶酶的含量。已开发出两种用于单次捐献或小批量血浆的S/D处理程序,并采用一次性袋系统。
将冷冻血浆样本解冻,在一次性袋子中于37℃用2%的三(正丁基)磷酸酯(TnBP)或于31℃用1%的TnBP和1%的 Triton X-45处理4小时。用7.5%的无菌蓖麻油对血浆样本进行三次萃取以去除TnBP和Triton X-45。经TnBP处理的血浆样本进一步进行澄清离心(3800×g,30分钟)。将最终的血浆样本分装到各个袋子中,并在-30℃冷冻。在程序的每个步骤评估血浆质量。
两种方法均使凝血因子(可凝纤维蛋白原、血管性血友病因子以及因子VIII、V、VII、IX、X和XI)、抗凝剂(蛋白C、蛋白S)、蛋白酶抑制剂(抗凝血酶、α2-抗纤溶酶)、总蛋白、白蛋白和免疫球蛋白的平均回收率大于90%。处理后的血浆样本的整体凝血试验正常。最终的TnBP和Triton X-45含量分别低于10 ppm和50 ppm。
血浆的S/D处理可在封闭袋系统中进行,且能维持血浆蛋白质量。该技术简单,比工业大规模S/D血浆处理方法具有优势,并且可在血站进行。